Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “STRONGYLOIDES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 991 records · Page 55Linked to original sources
PubMed1987

Treatment of strongyloides stercoralis with albendazole. A cure rate of 86 per cent.

A clinical trial concerning the efficacy of albendazole has been performed in an area outside the endemic zone. Sixty-eight patients were treated with albendazole in doses varying from 4-30 mg/kg/day for 3-6 days. A high cure rate of 86 per cent was obtained with albendazole 16 mg/kg/day for three days and repeated once after a fortnight. The albendazole was well tolerated and no side effects were imputed to the treatment. Successful treatment was confirmed by seven negative, consecutive coprocultures. The follow up period ranged from 35 to 615 days.

Adolescent↗
PubMed1991

[Clinical study on ivermectin against Strongyloides stercoralis].

We previously reported the efficacy of ivermectin (IVM) for the treatment of 23 strongyloidiasis patients. We now reported the efficacy and safety of IVM therapy on 54 patients. Fifty-four patients, 28 males and 26 females, received a single oral dose of IVM one hour before breakfast and this treatment was repeated 2 weeks later. The following results were obtained: 1) The cure rate at 2 weeks after the initial treatment was 92.5% (49 of 53 patients) and 2 weeks after the second course was 96.0% (48 of 50 patients). 2) Four patients (7.4%) complained of diarrhea (n = 2 patients), constipation (n = 1), borborygmus (n = 1), dizziness (n = 1), diplopia (n = 1) and peri-anal itching (n = 1) after the first treatment. Three patients (5.6%) complained of borborygmus (n = 1), itching (n = 1) and exanthema (n = 1) after the second treatment. But all symptoms were mild and required no treatment and subsided in a few days. 3) Positive rate of HTLV-1 antibody was 25.9% in the patients. As described above, although side effects occurred in some cases, they were mild and transient. From these results, we concluded that IVM is an effective drug for strongyloidiasis.

Adult↗